SecProbe.io

September 23, 2014

Via E -mail
Lisa A. Conte
Chief Executive Officer and President
Jaguar Animal Health, Inc.
185 Berry Street, Suite 1300
San Francisco, California 94107

Re: Jaguar Animal Health, Inc.
Amendment No. 1 to Registration Statement on Form S-1
Filed September 9, 2014
 File No. 333 -198383

Dear Ms. Conte :

We have reviewed your amended registration statement  and have the following
comments.  In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the
requested information .  If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.

After reviewing any amendment to your registration statement and the information you
provide in response to these  comments, we may have  additional comments.

Capitalization, page 46

1. We acknowledge  your response to previous comment 9.  Please revise your disclosure,
when you establish your anticipated offering price range, to disclose the amount of  the
contingent beneficial conversion feature charge to loss applicable to common
shareholders that will be recorded upon the completion of your offering related to your
Series A redeemable convertible preferred stock.

Business, page 62

2. We note your resp onse to comment 6. Please amend your disclosure to briefly describe
the material terms of this non -disturbance agreement when available.  Additionally,
please file this agreement as an exhibit pursuant to Item 601(b)(10) of Regulation S -K.

Lisa A. Conte
Jaguar Animal Health, Inc.
September 23, 2014
Page 2

 Next Steps and  Commercialization Plans, page 70

3. We note on page 70 that you expect to meet with the FDA in late August or early
September 2014.  Please update your disclosure regarding this meeting and the status of
your rolling NADA process for Canalevia for the treat ment of CID in dogs .

We urge all persons who are responsible for the accuracy and adequacy of the disclosure
in the filing to be certain that the filing includes the information the Securities Act of 193 3 and
all applicable Securities  Act rules require.   Since the company and its management are in
possession of all facts relating to a company’s disclosure, they are responsible for the accuracy
and adequacy of the disclosures they have made.

Notwithstanding our comments, in the event you request accelera tion of the effective date
of the pending regist ration statement please provide  a written statement from the company
acknowledging that:

 should the Commission or the staff, acting pursuant to delegated authority, declare the
filing effective, it does not foreclose the Commission from taking any action with respect
to the filing;

 the action of the Commission or the staff, acting pursuant to delegated authority, in
declaring the filing effective, does not relieve the company from its full responsibility for
the adequacy and accuracy of the disclosure in the filing; and

 the company  may not assert staff comments and the declaration of effectiveness as a
defense in any proceeding initiated by the Commission or any person under the federal
securities laws of the United States.

Please refer to Rules 460 and 461 regarding requests for  acceleration .  We will consider a
written request for acceleration of the effective date of the registration statement as confirmation
of the fact that those requesting acceleration are aware of their respective responsibilities under
the Securities Act of  1933 and the Securities Exchange Act of 1934 as they relate to the proposed
public offering of the securities specified in the above registration statement.  Please allow
adequate time  for us to review any amendment prior to the requested effective date o f the
registration statement.

You may contact Frank Wyman at (202) 551 -3660 or Mark Brunhofer at (202) 551 -3638
if you have questions regarding comments on the financial statements and related matters.

Lisa A. Conte
Jaguar Animal Health, Inc.
September 23, 2014
Page 3

 Please contact Matthew Jones at (202) 551 -3786, John Krug at (202) 551 -3862, or me at
(202) 551 -3715 with any other questions.

Sincerely,

 /s/ Daniel  Greenspan  for

Jeffrey P. Riedler
Assistant Director

cc:  Donald C. Reinke, Esq.
Marianne C. Sarrazin, Esq.
Reed Smith LLP
101 Second Street, Suite 1800
San Francisco, California 94105